Tumor antigen-presenting pathway (None)

The tumor antigen-presenting pathway is a complex, multi-component biological system essential for immune surveillance of cancer cells. It represents the cellular machinery responsible for processing intracellular and extracellular proteins into short peptides (typically 8-11 amino acids for MHC-I, longer for MHC-II) and displaying them on the cell surface bound to major histocompatibility complex molecules for recognition by T cells[5][9]. This pathway serves as a critical bridge between innate and adaptive immunity, enabling the immune system to distinguish between normal "self" proteins and aberrant proteins arising from tumors, including those derived from viral antigens, mutated gene products, overexpressed differentiation antigens, RNA-editing derived epitopes, post-translationally modified proteins, and proteasome-generated spliced peptides[2]. Tumors frequently evade immune destruction by subverting this pathway through multiple mechanisms: downregulation or loss of MHC molecules, defects in peptide processing machinery (TAP, proteasomes, ERAP1), mutations in β2-microglobulin, alterations in transcriptional regulators (CIITA, NLRC5, IRF1), and modulation of surface MHC expression through MARCH family ubiquitin ligases[4][10]. Some tumors show impaired responses to interferon-gamma stimulation, which normally upregulates antigen presentation components[4][10]. Understanding and targeting this pathway is crucial for cancer immunotherapy, as the effectiveness of immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies fundamentally depends on functional antigen presentation. Imaging techniques and biomarker assessments of this pathway are emerging as tools for patient stratification and treatment monitoring[9]. The classification of tumors based on their antigen presentation capacity (such as metabolism-type versus kinase-type pheochromocytomas) may guide therapeutic decisions, including potential combinations of kinase inhibitors with immunotherapy[6].

Other names

Antigen processing and presentation pathwayMHC antigen presentation pathwayTumor antigen processing pathwayMajor histocompatibility complex antigen presentation pathwayAntigen presentation machinery

Therapeutic strategies targeting this pathway include enhancement of antigen presentation through interferon stimulation, restoration of defective antigen presentation machinery, induction of immunogenic cell death to increase antigen availability, modulation of autophagy to enhance MHC-II presentation, and combined targeting of tumor-specific evasion mechanisms with immunotherapy.